Table 2.

Effects of various inhibitors on the TF-induced clotting time in human plasma


Inhibitor

[Inhibitor]1.5 × CT,*nM

Relative potency
TAP-ANV   0.80   86  
ANV 6L15   6.0   12  
ANV-KAPP  9.4   7.3  
ANV-KKTFPI  11   6.3  
ANV   29   2.4  
TAP   68   1  
TFPI   69   1  
E. coli TFPI1-160  2750   0.025  
6L15
 
5900
 
0.012
 

Inhibitor

[Inhibitor]1.5 × CT,*nM

Relative potency
TAP-ANV   0.80   86  
ANV 6L15   6.0   12  
ANV-KAPP  9.4   7.3  
ANV-KKTFPI  11   6.3  
ANV   29   2.4  
TAP   68   1  
TFPI   69   1  
E. coli TFPI1-160  2750   0.025  
6L15
 
5900
 
0.012
 

Pooled human plasma (100 μL) was mixed with an equal volume of an inhibitor dissolved in buffer (10 mM Tris, pH 7.4; 0.15 M NaCl; 1 mg/mL BSA; 0.02% NaN3) at varying concentrations. Dade Innovin was diluted 1:100 with buffer (75 mM NaCl, 12.5 mM CaCl2, 0.5 mg/mL BSA, 0.02% NaN3) for the assay. Clotting times were determined with an ACL 200 coagulation analyzer.

*

Concentration of inhibitor that prolongs the TF-induced clotting time 1.5-fold relative to control (ie, from 40.7 to 61.1 seconds)

Calculated by dividing [Inhibitor]1.5 × CT for TFPI by the value for the other specified inhibitor

Close Modal

or Create an Account

Close Modal
Close Modal